For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...

Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin ...

Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.

Discover key gene signatures that could help predict the efficacy of immune checkpoint blockade therapy in patients with ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on JAZZ stock, giving a Buy rating today. Jason Gerberry ...

Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is ...

Treatment with cediranib or cediranib plus olaparib is not superior to standard of care (SOC) in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a ...

In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned interim analysis found the ...